Heat shock proteins (HSPs) represent a critical component of the cellular proteostasis network, functioning as molecular chaperones that facilitate protein folding, prevent aggregation, and coordinate protein quality control mechanisms. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), the proteostasis network is severely compromised, leading to accumulation of hyperphosphorylated tau (4R-tau) in neurofibrillary tangles. This section covers advanced therapeutic strategies targeting HSP70/HSP90 modulation, small molecule HSP inducers, pharmacological chaperones, tau aggregation blockers, NET (neurofilament light chain) assessment, and drug interactions for CBS/PSP patients.
The rationale for targeting heat shock proteins in CBS/PSP is compelling:
The HSP70 family of proteins constitutes the primary cellular defense against protein misfolding and aggregation. In CBS/PSP, several HSP70 family members are dysregulated:
Key HSP70 Proteins:
| Protein | Gene | Primary Function | Status in CBS/PSP |
|---|---|---|---|
| HSP70-1A | HSPA1A | Inducible chaperone, tau binding | Decreased in affected brain regions |
| HSP70-1B | HSPA1B | Inducible chaperone | Compensatorily increased |
| HSP70-2 | HSPA2 | Testis-specific, neuronal expression | Decreased |
| GRP78/BiP | HSPA5 | ER chaperone, unfolded protein response | Increased (compensatory) |
| HSC70 | HSPA8 | Constitutive chaperone, clathrin-mediated transport | Relatively preserved |
The inducible HSP70 (HSPA1A) is particularly important for tauopathy therapeutics because it:
HSP90 plays a critical role in tauopathy as it serves as a hub for multiple signaling pathways and client proteins relevant to neurodegeneration:
HSP90 Client Proteins Relevant to CBS/PSP:
HSP90 inhibition causes degradation of these client proteins and simultaneously induces HSP70 via HSF1 activation, making it a dual-action therapeutic strategy.
Geldanamycin is a natural product that specifically inhibits the ATPase activity of HSP90 by binding to its N-terminal domain. However, geldanamycin itself is too toxic for clinical use. Several derivatives have been developed:
Geldanamycin Analogs in Development:
| Compound | Company | Status | Key Features |
|---|---|---|---|
| 17-DMAG (Alvespimycin) | Kosan/NCI | Preclinical | Water-soluble, BBB-penetrant |
| 17-AAG (Tanespimycin) | Kosan | Phase I/II (cancer) | Limited BBB penetration |
| PU-H71 | OncoSynergy | Preclinical | Selective tumor HSP90 |
| NVP-HSP990 | Novartis | Discontinued | Oral bioavailability |
The mechanism of action involves:
Celastrol is a natural triterpenoid from Tripterygium wilfordii (Thunder God Vine) that has shown significant neuroprotective properties:
Mechanism of Action:
Preclinical Evidence:
Clinical Considerations:
Tolfenamic acid is an NSAID that has been repurposed for neurodegenerative disease therapy:
Mechanism:
Clinical Development:
The "toggled" compounds represent a newer class of HSP90 modulators designed to selectively induce HSP70 without the toxicity associated with classical HSP90 inhibitors:
Advantages of Toggled Compounds:
| Compound | Source | HSP Induction | Evidence Level |
|---|---|---|---|
| Withaferin A | Ashwagandha | HSF1 activation | Strong preclinical |
| Curcumin | Turmeric | Moderate HSP70 | Mixed clinical results |
| Resveratrol | Grapes | SIRT1-mediated | Preclinical |
| Sulforaphane | Broccoli | Nrf2 + HSF1 | Preclinical |
Pharmacological chaperones are small molecules that specifically bind to target proteins, stabilizing their native conformation and facilitating proper folding. For CBS/PSP, the focus is on tau aggregation inhibitors and proteostasis modulators:
These compounds directly inhibit the polymerization of tau into oligomers and fibrils:
Classes of Tau Aggregation Inhibitors:
| Class | Example Compounds | Mechanism | Clinical Status |
|---|---|---|---|
| Phenothiazines | Methylene blue | Prevents β-sheet formation | Phase 3 (AD) |
| Phenylthiazoles | Rember (TRx0237) | Tau aggregation inhibition | Phase 3 (AD) |
| Thienopyridazines | AZD5904 | Tau oligomerization | Phase 1 |
| polyphenols | EGCG | Anti-aggregation | Phase 2 |
| HSP70-based | No small molecule | N/A | Research |
Methylene Blue Derivatives:
Concept:
Emerging Candidates:
AAV-mediated HSP70 delivery represents a promising approach:
Approach:
Preclinical Results:
Small Molecule HSP70 Activators:
| Compound | Target | Mechanism | Status |
|---|---|---|---|
| 2-phenylethynesulfonamide (PES) | HSP70 | Allosteric activation | Preclinical |
| YD-1 | HSP70 | ATPase modulation | In vitro |
| JG-98 | HSP70 | Allosteric inhibitor | Chemical probe |
Heat shock factor 1 (HSF1) is the master regulator of heat shock protein expression. Direct HSF1 activation bypasses the need for proteostatic stress:
HSF1 Activators:
NfL serves as a key biomarker for disease progression and treatment response in CBS/PSP:
Clinical Relevance:
Target Ranges:
Biomarker Panel for HSP-Targeted Therapy:
| Biomarker | Sample | Frequency | Expected Change |
|---|---|---|---|
| Total tau | CSF | Baseline + 6 months | Decrease |
| Phospho-tau181 | CSF/Plasma | Baseline + 6 months | Decrease |
| NfL | Plasma | Every 3 months | Decrease |
| HSP70 levels | PBMCs | Baseline + 3 months | Increase |
When assessing HSP-targeted therapies in CBS/PSP clinical trials:
Primary Endpoints:
Secondary Endpoints:
HSP90 Inhibitors:
| Interacting Drug | Effect | Management |
|---|---|---|
| Statins | Increased myopathy risk | Monitor CK |
| Anticoagulants | Bleeding risk | Monitor INR |
| Immunosuppressants | Altered metabolism | Dose adjustment |
| Chemotherapy | Enhanced toxicity | Avoid combination |
Celastrol:
| Interacting Drug | Effect | Management |
|---|---|---|
| Immunosuppressants | Additive immunosuppression | Avoid |
| NSAIDs | GI toxicity | Separate dosing |
| Blood pressure meds | Hypotension | Monitor BP |
HSP90 Inhibitors:
Celastrol:
For HSP90 Inhibitor Therapy:
Ideal Candidates for HSP-Targeted Therapy:
Exclusion Criteria:
Based on available evidence, consider the following approach:
For Celastrol (off-label/natural compound):
For Tolfenamic Acid (if available):
For Combination Approaches:
Morning Protocol:
Evening Protocol:
Monitoring Schedule:
| Intervention | Evidence Level | Key Studies |
|---|---|---|
| HSP90 inhibitors | Strong | Multiple mouse model studies showing tau reduction |
| Celastrol | Moderate-Strong | P301L mouse studies positive |
| HSP70 gene therapy | Moderate | AAV-HSPA1A effective in mice |
| Tolfenamic acid | Moderate | Phase 1 complete, human data emerging |
| Tau aggregation blockers | Strong | Methylene blue has clinical data |